BioSpace News Archive

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, on June 16, 2023, filed with the SEC its financial results and related management’s discussion for the first quarter ended March 31, 2023.

Poseida Therapeutics, Inc. today announced it is set to join both the broad-market Russell 3000 ® and small-cap Russell 2000 ® Indexes at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. market opens today, according to a preliminary list of additions posted following the close of the U.S. markets on May 19, 2023.

Corium, LLC announced today that the peer-reviewed journal Frontiers in Psychiatry published an analysis of a yearlong open-label safety study of Corium’s attention-deficit hyperactivity disorder (ADHD) medicine AZSTARYS (serdexmethylphenidate [SDX] and dexmethylphenidate [d-MPH]).

Waters and Princeton University signed a multi-year agreement to take on real-world challenges in biologics and materials research.

Fusion Pharmaceuticals Inc. today announced the presentation of interim data from the dose escalation portion of the Phase 1 trial of [225Ac]-FPI-1434 (FPI-1434) in patients with solid tumors expressing IGF-1R.

GlycoMimetics, Inc. today announced that it is set to join the Russell Microcap Index at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. market opens on June 26, 2023.

Cognito Therapeutics today announced that it will present four scientific abstracts at the Alzheimer’s Association International Conference 2023 (AAIC).

Shionogi & Co., Ltd. announced that Shionogi Inc., a New Jersey-based subsidiary of Shionogi, has entered into a definitive agreement pursuant to which Shionogi Inc. will acquire Qpex Biopharma, Inc.

Savara Inc. today announced that enrollment has been completed for the pivotal Phase 3 IMPALA-2 trial.

OMAPiX announced strategic partnerships with Vizgen, Inc., Resolve Biosciences, and Ultivue, Inc.